top of page
MedMira receives CE mark for its VYRAâ„¢ CoV2Flu Antigen Test
Halifax, Nova Scotia, 11 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™...
MedMira
Jan 11, 20233 min read
MedMira's G4 HIV (FDA approved) rapid test - an independent evaluation by the CDC
Performance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens...
MedMira
Jan 5, 20231 min read
Point-of-Care Diagnostic for Trichomonas vaginalis based on MedMira’s RVF Technology®
Halifax, Nova Scotia, 3 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the publication of Point-of-Care Diagnostic...
MedMira
Jan 3, 20234 min read
Point-of-Care Diagnostic for Trichomonas vaginalis based on MedMira’s RVF Technology®
Halifax, Nova Scotia, 3 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the publication of Point-of-Care Diagnostic...
MedMira
Jan 3, 20234 min read
MedMira Introduces VYRA TriDemic
Halifax, Nova Scotia, 29 December, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) presents its latest addition to the VYRATMproduct...
MedMira
Dec 29, 20223 min read
MedMira's Multiplo TP/HIV Rapid Test: One Test, More Answers.
A study completed by the Indian Red Cross Blood Society showed that MedMira's Multiplo TP/HIV Rapid Test is your immediate quality...
MedMira
Oct 29, 20222 min read
bottom of page